Oncolytics Biotech Advances Pelareorep Immunotherapy Trial for Pancreatic Cancer Treatment

Oncolytics Biotech Pioneers New Immunotherapy Trial for Pancreatic Cancer

Oncolytics Biotech Inc. is making significant strides in the development of pelareorep, an innovative immunotherapy agent aimed at treating pancreatic ductal adenocarcinoma (PDAC). The company announces an upcoming meeting with the U.S. Food and Drug Administration (FDA) scheduled for mid-November 2025, where it plans to discuss the details of a pivotal registration-directed clinical trial. This trial is designed with a three-arm structure, comparing the standard chemotherapy regimen Gemcitabine combined with nab-paclitaxel against two experimental arms that include pelareorep, with one also incorporating a checkpoint inhibitor (CPI). The primary measure of success will be Overall Survival (OS), and the trial intends to demonstrate statistical significance over the control group.

The trial's framework reflects a strategic approach to harnessing pelareorep’s potential in an area notorious for poor prognosis. Recent post-hoc analyses reveal that patients receiving pelareorep alongside chemotherapy exhibit a two-year survival rate of 22%, a substantial improvement over the 9% seen with chemotherapy alone. This compelling data underscores the promise of pelareorep to transform treatment paradigms for PDAC, a cancer that has historically been resistant to effective therapies. CEO Jared Kelly highlights this potential, noting that the successful approval of pelareorep could represent a groundbreaking milestone in oncology as the first immunotherapy for first-line pancreatic cancer therapy.

In addition to its focus on pancreatic cancer, Oncolytics is also advancing pelareorep in combination therapies for metastatic breast cancer, both of which have garnered Fast Track designation from the FDA. This expedited pathway is designed to facilitate the development and review of drugs that treat serious conditions and fill an unmet medical need. As the company progresses, it is actively seeking strategic partnerships to bolster the development of pelareorep and maximize its commercial impact in the oncology landscape.

As Oncolytics Biotech prepares for this critical trial and regulatory discussions, the company stands at the forefront of innovative cancer therapies, aiming to reshape treatment options for patients facing some of the most challenging cancers.